Sequana Medical NV (EBR:SEQUA)

Market Cap	54.50M
Revenue (ttm)	105.50K
Net Income (ttm)	-44.65M
Shares Out	53.43M
EPS (ttm)	-1.22
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	168,700
Average Volume	237,841
Open	1.002
Previous Close	1.020
Day's Range	0.998 - 1.038
52-Week Range	0.471 - 4.390
Beta	-0.05
RSI	46.88
Earnings Date	Jun 13, 2025

About Sequana Medical NV

Sequana Medical NV develops and commercializes treatments for patients with diuretic-resistant fluid overload in liver disease, cancer, and heart failure in Belgium, Germany, France, Switzerland, and internationally. The company products pipeline comprises alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; and Direct Sodium Removal (DSR) for the treatment of fluid overload spread across the body and heart failure. Sequana Medical NV was founded in 2006 and is headquartered in Gent, B...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2006
• Employees: 48
• Stock Exchange: Euronext Brussels
• Ticker Symbol: SEQUA

Financial Performance

In 2024, Sequana Medical NV's revenue was 105,500, a decrease of -85.19% compared to the previous year's 712,173. Losses were -44.65 million, 37.1% more than in 2023.